Radionuclide-Drug Conjugates (RDCs)
Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs. This entry provides molecular intermediates that can be used in the synthesis and research of RDC.
Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products
All Product Categories
-
Radionuclide-Drug Conjugates (RDCs) Related Products (230)
Related Products (230)
-
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
-
p-SCN-Bn-PCTA hydrochloride
0 ImagesCat. No.: HY-W782087ACAS No.: 2649490-34-4p-SCN-Bn-PCTA hydrochloride is a Bifunctional Chelator used for radiometal labeling. p-SCN-Bn-PCTA hydrochloride can conjugate with peptides or antibodies via its isothiocyanate group. PCTA-RGD, formed by the conjugation of p-SCN-Bn-PCTA with cyclo-RGDyK, retains binding activity towards αvβ3 integrin with an IC50 of 1.8 μM. p-SCN-Bn-PCTA hydrochloride can be used for the construction of PET radiotracers and imaging studies related to pancreatic cancer, colorectal cancer, and tumor angiogenesis.
-
NH2-NODAGA TFA
0 ImagesCat. No.: HY-164575ACAS No.: 3053227-80-5NH2-NODAGA TFA is an amino-modified NODAGA-type bifunctional chelator, specifically designed for amidation coupling with targeting ligands via squaric acid (SA), followed by coordination with radionuclides (e.g., 68Ga, 177Lu). NH2-NODAGA TFA can be coupled with diethyl squarate to form a PSMA inhibitor conjugate, which is used in prostate cancer research.
-
DOTA-Octreotide
0 ImagesCat. No.: HY-P10273CAS No.: 209277-09-8DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
(S)-DOTAGA.(SA.FAPi)2
0 ImagesCat. No.: HY-159767ACAS No.: 2417089-06-4(S)-DOTAGA.(SA.FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging.
-
Icopezil
0 ImagesCat. No.: HY-105157CAS No.: 145508-78-7Synonyms: CP-118954Icopezil (CP-118954) is an orally active, selective AchE inhibitor with an IC50 of 0.33 nM. Icopezil increases acetylcholine levels in the brain and striatum of mammals, induces centrally mediated tremors and peripherally mediated salivation, and improves working memory performance in aged dogs. Icopezil serves as a parent compound for radioiodine-labeled acetylcholinesterase imaging agents. Icopezil is applicable to research related to Alzheimer's disease.
-
DOTA-BP1
0 ImagesCat. No.: HY-P11257DOTA-BP1 is a DOTA-modified BP1 (BCMA-targeting peptide). DOTA-BP1 can be radiolabeled with [68Ga]Ga to produce a BCMA-targeting PET tracer. DOTA-BP1 can be used in the research of detecting BCMA in multiple myeloma.
-
DOTA Conjugated JM#21 derivative 7
0 ImagesCat. No.: HY-P10444CAS No.: 3033865-40-3DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney. DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
cT84.66
0 ImagesCat. No.: HY-P992339cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies.
-
Cyclic αvβ6
0 ImagesCat. No.: HY-P11576CAS No.: 2089299-82-9Cyclic αvβ6 (Compound c(FRGDLAFp(NMe)K)) is a αvβ6-integrin-specific cyclic nonapeptide. Cyclic αvβ6 can be coupled with 68Ga-labeled monomeric triazacyclononane-triphosphinate (TRAP). Cyclic αvβ6 can be used in PET imaging studies for cancers including head and neck cancer and pancreatic cancer.
-
SC691
0 ImagesCat. No.: HY-174808CAS No.: 2577994-10-4SC691 is a PSMA inhibitor. SC691 can be labeled with 68Ga(III). SC691 can be used for imaging diagnosis of prostate cancer.
-
HYNIC-iPSMA
0 ImagesCat. No.: HY-P5292CAS No.: 2192215-74-8HYNIC-iPSMA is a PSMA-targeted ligand for tumor molecular imaging, with a Ki value of 3.11 nM. HYNIC-iPSMA consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC acts as a chelating moiety to link radionuclides to the targeting molecule; iPSMA is a specific inhibitor that targets Prostate-Specific Membrane Antigen (PSMA). 68Ga-labeled iPSMA is used for prostate cancer detection via PET imaging, while the further developed 99mTc-EDDA/HYNIC-iPSMA TFA exhibits excellent specificity and sensitivity. HYNIC-iPSMA can be used for the synthesis and research of radionuclide-conjugated drugs (RDC).
-
DOTA-TH10
0 ImagesCat. No.: HY-P11838DOTA-TH10 is a CSPG4-targeted probe that enables targeted enrichment in tumors with overexpressed CSPG4. 68Ga-radiolabeled DOTA-TH10 specifically binds to CSPG4, allowing visualization of CSPG4 expression. 68Ga-radiolabeled DOTA-TH10 exhibits significant tumor uptake capacity in pancreatic cancer and gastric cancer models. DOTA-TH10 can be used for research on pancreatic cancer and gastric cancer.
-
DOTA-ubiquicidin (29–41)
0 ImagesCat. No.: HY-P10307DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT. DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
DPA-713
0 ImagesDPA-713 is a blood-brain barrier-permeable, specific translocator protein (TSPO) ligand. DPA-713 binds exclusively to TSPO without interacting with central benzodiazepine receptors; its binding can be competitively displaced by excess unlabeled TSPO ligands. After 11C labeling, DPA-713 enables sensitive quantitative analysis of TSPO expression associated with microglial activation, allowing differentiation between normal and pathological brain tissues. DPA-713 can be used in studies related to neuroinflammation, neurodegenerative diseases, and recently onset schizophrenia.
-
Propargyl-DOTA-tris(tBu)ester
0 ImagesCat. No.: HY-W999782CAS No.: 911197-00-7Propargyl-DOTA-tris(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging.
-
Depreotide
0 ImagesCat. No.: HY-114133CAS No.: 161982-62-3Depreotide is a nove tumor tarcer, can be complexed with technetium-99m (99mTc-depreotide) for optimal imaging properties. 99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research. Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
